Press Releases

Shire delivers strong quarter driven by 3m of new product sales

Thursday 31st July 2008

Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment

Tuesday 15th July 2008

Shire to add new orphan drug to its HGT portfolio - EU launch imminnent

Thursday 3rd July 2008

Graham Hetherington appointed Chief Financial Officer and Board Director at Shire

Tuesday 10th June 2008

First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide

Tuesday 27th May 2008

Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans

Friday 9th May 2008

Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair

Thursday 1st May 2008

Publication of Supplementary Prospectus

Tuesday 29th April 2008

Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy

Thursday 24th April 2008

FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

Wednesday 23rd April 2008

Shire and TAP Agree to Co-promote LIALDA™ (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

Wednesday 26th March 2008

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

Sunday 9th March 2008

RENOVO ANNNOUNCES JUVISTA® PHASE 2 TRIAL RESULTS IN SCAR REVISION AND BREAST AUGMENTATION SURGERY

Monday 3rd March 2008

Excellent performance across all areas of the business and accelerating new product sales drive revenue growth of 36%

Thursday 21st February 2008

Shire’s ELAPRASE® (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome

Wednesday 13th February 2008

Full Year 2007 results date notification – 21 February 2008

Tuesday 12th February 2008

Shire Completes Fosrenol® Roll-Out in Major European Markets With Launch in Spain

Wednesday 16th January 2008

FDA Approves Additional Dosage Strengths of Shire’s ADHD Treatment VYVANSE™ (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients

Thursday 3rd January 2008

Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation

Friday 14th December 2007

Board Changes

Thursday 13th December 2007

Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration

Friday 30th November 2007

Shire expands its Human Genetic Therapies pipeline through in-licensing agreement with Amicus Therapeutics

Thursday 8th November 2007

Shire announces results of Fosrenol® study in pre-dialysis CKD stage 3 & 4 patients

Tuesday 6th November 2007

David Mott appointed Non Executive Director at Shire

Wednesday 31st October 2007

Third quarter 2007 results date notification

Wednesday 17th October 2007

Shire divests non-core product portfolio to Almirall

Monday 8th October 2007

Shire’s ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome

Thursday 4th October 2007

Executive Change

Monday 24th September 2007

Expiry of Hart-Scott-Rodino waiting period for JUVISTA® (human TGFβ3)

Wednesday 15th August 2007

Uncertainty remains for newly diagnosed patients with mild Alzheimer’s disease and their families as the Judicial Review judgement is revealed

Friday 10th August 2007

2007 guidance upgraded as revenue growth accelerates

Tuesday 26th June 2007

Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder Fosrenol® Launches In Europe

Monday 25th June 2007

Shire Receives Approvable Letter from FDA for INTUNIV™ (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD

Thursday 21st June 2007

Shire plc News Alert Shire in-licenses JUVISTA(R) (human TGFâ3) from Renovo

Wednesday 20th June 2007

Shire’s ELAPRASE™ (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome

Thursday 14th June 2007

Shire plc have approval for SPD465

Saturday 19th May 2007

Investor Relations

Monday 14th May 2007

Shire welcomes news on Judicial review on Alzheimer's drugs

Friday 11th May 2007

VYVANSE DEA says isas a Schedule II controlled substance

Thursday 3rd May 2007

Shire plc announces refinancing of bank facilities

Wednesday 2nd May 2007

Shire plc announces the pricing of its offering of US,000 million principal amount of Convertible Bonds

Wednesday 2nd May 2007

CEO of Shire will be presenting at the Deutsche Bank 32nd Annual Health Care Conference

Tuesday 1st May 2007

Shire plc announces results for the first quarter 2007.

Wednesday 25th April 2007

Shire Successfully Completes Tender Offer for New River Shares

Wednesday 18th April 2007

Results of Extraordinary General Meeting held on 16 April 2007

Monday 16th April 2007

Shire Announces Posting of Circular, Date of Extraordinary General Meeting and Extension of Tender Offer for New River Shares until April 17, 2007

Tuesday 27th March 2007

IFRS results for the year ending December 31, 2006.

Friday 23rd March 2007

ADDERALL XR® - Shire Files Suit against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf

Wednesday 21st March 2007

Shire plc News Alert Shire begins external search for President of successful Human Genetic Therapies business, on retirement of David Pendergast at the end of 2007

Tuesday 20th March 2007

Shire plc News Alert LIALDA with MMX Technology for UC, Now Available

Tuesday 20th March 2007

Shire Announces Expiration of Hart-Scott-Rodino Waiting Period

Monday 19th March 2007

RESULT OF EQUITY PLACING

Tuesday 20th February 2007

Full Year 2006 Results Date Notification - 23 February 2007

Wednesday 14th February 2007

Shire licenses the North American rights for SPD754 (apricitabine) to Avexa Ltd

Monday 22nd January 2007

FDA Approves LIALDA™ (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

Tuesday 16th January 2007

ELAPRASE® for the treatment of Hunter syndrome approved by the European Commission

Thursday 11th January 2007

Shire receives label agreement in Europe for ulcerative colitis treatment, Mezavant™ (mesalazine)

Thursday 14th December 2006

Dr Jeffrey Leiden appointed Non Executive Director at Shire

Tuesday 12th December 2006

Australian Government TGA approves registration of Solaraze® 3% gel (diclofenac sodium) for the management of actinic keratosis

Tuesday 28th November 2006

Shire sues Andrx Pharmaceuticals, L.L.C.

Friday 10th November 2006
More from Dods
Advertise

Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.